Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic

References

• Aznar MÁ, Lasa-Saracíbar B, Estella-Hermoso De Mendoza A, et al. (2013). Efficacy of edelfosine lipid nanoparticles in breast cancer cells. Int J Pharm 454:720–6
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MÁ, Gascón AR, et al. (2013). Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Controll Release 166:115–23
   PubMed Web of Science ®Google Scholar
• Bhandari R, Kaur IP. (2013). Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm 441:202–12
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–84
   PubMed Web of Science ®Google Scholar
• Bondì ML, Craparo EF, Giammona G, et al. (2007). Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv 14:61–7
   PubMed Web of Science ®Google Scholar
• Brugè F, Damiani E, Puglia C, et al. (2013). Nanostructured lipid carriers loaded with CoQ10: effect on human dermal fibroblasts under normal and UVA-mediated oxidative conditions. Int J Pharm 455:348–56
   PubMed Web of Science ®Google Scholar
• Bunjes H, Westesen K, Koch MH. (1996). Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 129:159–73
   Web of Science ®Google Scholar
• Cai Y, Yap C, Wang Z, et al. (2010). Solubilization of vorinostat by cyclodextrins. J Clin Pharm Ther 35:521–6
   PubMed Web of Science ®Google Scholar
• Chandran P, Kavalakatt A, Malarvizhi GL, et al. (2014). Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases. Nanomed-Nanotechnol 10:721–32
   PubMed Web of Science ®Google Scholar
• Chen C-C, Tsai T-H, Huang Z-R, et al. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74:474–82
   PubMed Web of Science ®Google Scholar
• Cirri M, Bragagni M, Mennini N, et al. (2012). Development of a new delivery system consisting in “drug – in cyclodextrin – in nanostructured lipid carriers” for ketoprofen topical delivery. Eur J Pharm Biopharm 80:46–53
   PubMed Web of Science ®Google Scholar
• Delgado D, Del Pozo-Rodríguez A, Solinís MÁ, et al. (2011). Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway. Eur J Pharm Biopharm 79:495–502
   PubMed Web of Science ®Google Scholar
• Dudhipala N, Veerabrahma K. (2014). Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Delivery Early online:1–10. doi:10.3109/10717544.2014.914986
   Web of Science ®Google Scholar
• Dwivedi P, Khatik R, Khandelwal K, et al. (2014). Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm 466:321–7
   PubMed Web of Science ®Google Scholar
• Hong W, Chen D, Jia L, et al. (2014). Thermo- and pH-responsive copolymers based on PLGA-PEG-PLGA and poly(l-histidine): synthesis and in vitro characterization of copolymer micelles. Acta Biomater 10:1259–71
   PubMed Web of Science ®Google Scholar
• Jia L, Shen J, Zhang D, et al. (2012). In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol 50:523–9
   PubMed Web of Science ®Google Scholar
• Jia L-J, Zhang D-R, Li Z-Y, et al. (2010). Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv 17:11–18
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’connor OA, Krug LM, et al. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–31
   PubMed Web of Science ®Google Scholar
• Konsoula R & Jung M. (2008). In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. Int J Pharm 361:19–25
   PubMed Web of Science ®Google Scholar
• Kumar A, Ahuja A, Ali J, et al. (2014). Curcumin-loaded lipid nanocarrier for improving bioavailability, stability and cytotoxicity against malignant glioma cells. Drug Delivery Early online:1–16. doi:10.3109/10717544.2014.909906
   Web of Science ®Google Scholar
• Lin X, Li X, Zheng L, et al. (2007). Preparation and characterization of monocaprate nanostructured lipid carriers. Colloid Surface A 311: 106–11
   Web of Science ®Google Scholar
• Marks P. (2007). Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351–6
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Miller T, et al. (2004). Histone deacetylase inhibitors. Adv Cancer Res 91:137–68
   PubMed Web of Science ®Google Scholar
• Minelli R, Occhipinti S, Gigliotti C, et al. (2013). Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models. Brit J Pharm 170:233–44
   PubMed Web of Science ®Google Scholar
• Mohamed EA, Zhao Y, Meshali MM, et al. (2012). Vorinostat with sustained exposure and high solubility in poly (ethylene glycol)-b-poly (dl-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. J Pharm Sci 101:3787–98
   PubMed Web of Science ®Google Scholar
• Mussi SV, Silva RC, Oliveira MCD, et al. (2013). New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 48:282–90
   PubMed Web of Science ®Google Scholar
• Poudel BK, Marasini N, Tran TH, et al. (2012). Formulation, characterization and optimization of valsartan self-microemulsifying drug delivery system using statistical design of experiment. Chem Pharm Bull 60:1409–18
   PubMed Web of Science ®Google Scholar
• Ramasamy T, Tran TH, Cho HJ, et al. (2013). Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: physicochemical and biological characterization. Pharm Res 31:1302–14
   PubMed Web of Science ®Google Scholar
• Richon V. (2006). Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Brit J Cancer 95:S2–6
   Web of Science ®Google Scholar
• Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–43
   PubMed Web of Science ®Google Scholar
• Tran TH, Poudel BK, Marasini N, et al. (2013). Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent. Inter J Pharma 443:50–7
   PubMed Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Truong DH, et al. (2014). Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm Res 31:1978–88
   PubMed Web of Science ®Google Scholar
• Tsai M-J, Huang Y-B, Wu P-C, et al. (2011). Oral apomorphine delivery from solid lipid nanoparticleswith different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 100:547–57
   PubMed Web of Science ®Google Scholar
• Tsai M-J, Wu P-C, Huang Y-B, et al. (2012). Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm 423:461–70
   PubMed Web of Science ®Google Scholar
• Xu P, Yin Q, Shen J, et al. (2013). Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS. Int J Pharm 454:21–30
   PubMed Web of Science ®Google Scholar
• Yuan H, Chen C-Y, Chai G-H, et al. (2013). Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol Pharm 10:1865–73
   PubMed Web of Science ®Google Scholar
• Zhuang C-Y, Li N, Wang M, et al. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394:179–85
   PubMed Web of Science ®Google Scholar